Save 50% on a 3-month Digiday+ membership. Ends Dec 12.
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
‘A trader won’t need to leave our platform’: PMG builds its own CTV buying platform
The platform, called Alli Buyer Cloud, sits inside PMG’s broader operating system Alli. It’s currently in alpha testing with three clients.
Why 2026 could be Snap’s biggest year yet – according to one exec
Snap’s senior director of product marketing, Abby Laursen talked to Digiday about its campaign automation plans for 2026.
‘We just did the math’: The new baseline for ad tech transparency
Ad execs said the industry is shifting toward a renewed transparency push driven as much by day-to-day operational pressure as by principle.